|
Recent Developments |
|
03-DEC-18
Sun Pharmaceutical Industries, today announced that Sun Pharma has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL.
28-NOV-18
Sun Pharmaceutical Industries announced that Sun Pharma has entered into a definitive agreement to acquire Pola Pharma Inc. (Pola Pharma), a Japanese pharmaceutical company engaged in research
24-OCT-18
Sun... More.. |
| Business Profile |
Future Plans |
|
| CEO Talk | | Sun Pharma firmly believes in optimising returns on available resources. It now intends to extend this philosophy to the area of new drug discovery Dilip Shanghvi |
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Dec-2017(9) | 31-Mar-2017(12) | 31-Mar-2016(12) | | Net sales | 56715.90 | 76501.80 | 71743.20 | | Other Income | 9510.80 | 5144.10 | 2172.40 | | Total Income | 66226.70 | 81645.90 | 73915.60 | | Cost of goods sold | 60273.30 | 79792.60 | 79474.20 | | OPBDIT | 5953.40 | 1853.30 | -5558.60 | | PAT | -6734.40 | -349.50 | -10733.60 | | Gross Block | - | - | - | | Equity capital | - | - | 2406.60 | | EPS (Rs.) | - | - | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 9.0 | 2.3 | -7.5 | | Net margin (% of OI) | -10.2 | -0.4 | -14.5 |
|
|
Detailed Financials
|
|
|
|
|
